Evidence map›Paper›PMID 42495793›Full record

ArticleBioanalysis

Potential remote measurement of C-peptide using a minimally invasive and convenient sampling technique.

Kathryn Duschean, Nina Vujovic, Emad Dumar, Lili Yu, Fedelis Mutiso, Allison B Goldfine, Arkady Gusev, Dmitri Mikhailov, Arvind Kinhikar

Abstract read
In one paragraph

Article in Bioanalysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kathryn DuscheanBiomarker Development, BioMedical Research, Novartis, Cambridge, MA, USA.
Nina VujovicClinical Sciences and Innovation, BioMedical Research, Novartis, Cambridge, MA, USA.
Emad DumarBiomarker Development, BioMedical Research, Novartis, Cambridge, MA, USA.
Lili YuBiomarker Development, BioMedical Research, Novartis, Cambridge, MA, USA.
Fedelis MutisoEarly Development-Advanced Quantitative Sciences, BioMedical Research, Novartis, Cambridge, MA, USA.
Allison B GoldfineTranslational Medicine Discovery & Profiling, BioMedical Research, Novartis, Cambridge, MA, USA.
Arkady GusevBiomarker Development, BioMedical Research, Novartis, Cambridge, MA, USA.
Dmitri MikhailovBiomarker Development, BioMedical Research, Novartis, Cambridge, MA, USA.
Arvind KinhikarBiomarker Development, BioMedical Research, Novartis, Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn clinical research, alternatives to venipuncture can reduce participant burden and increase accessibility and sampling opportunities for biomarkers. Residual pancreatic beta-cell function is assessed in clinical research and in diabetes care using fasting and stimulated C-peptide measurements, and changes are assessed over time. Operational, technical, and acceptability considerations of utilizing Tasso+ SST devices for C-peptide collection compared to venipuncture-derived serum samples were investigated. METHODOLOGY: Samples were collected from prospectively enrolled healthy participants via Third Generation Tasso+ SST micro-sampling devices and phlebotomy. Eleven fasted Tasso+ samples collected on-site or remote underwent alternative handling conditions and were evaluated for consistency, quality, and stability. Participants responded to device acceptability questionnaires.

resultsThe Tasso+ SST micro-sampling device showed excellent concordance with simultaneous venipuncture-derived fasted C-Peptide, with concentration being largely conserved in healthy volunteers despite alternative sample handling. Delayed centrifugation over 72 hours caused no consequential degradation of C-peptide when kept at 4°C. Questionnaire responses indicate acceptable device usability and associated comfort levels.

conclusionFasting C-peptide levels can be accurately collected using micro-sampling collection techniques. Tasso+ C-peptide stability is seen when kept at 4°C. Micro-sampling devices can be used with shipping mechanisms (without centrifugation) to decrease participant burden, expand trial populations, and aid biomarker measurements.

Indexed as

Blood Specimen CollectionC-PeptideAdultFemaleHumansMalePhlebotomyC-PeptideC-peptidedecentralizeddiabetesinsulinlow volumemetabolicmicro-samplingminimally invasive

Identifiers

PMID42495793
PMCPMC13557574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.